Psy103 - Modelling Average Cost and Cost-Per-Responder for Biological Treatments for Moderate-To-Severe Plaque Psoriasis With Dose Escalation and Real-World Drug Survival

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2678
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy

Global and Regional Health Technology Assessment
Health Policy
2019English

Psy83 - Impact of Dose Escalation on Average Cost and Cost-Effectiveness of Anti-TNF and Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy84 - Impact of High Discontinuation Rates for Secukinumab on Average Costs and Cost-Effectiveness Relative to Other Biological Treatments of Moderate-To-Severe Plaque Psoriasis in Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy29 - Real-World Discontinuation of Biological Treatments in Moderate-To-Severe Plaque Psoriasis Over the First 5 Years of Treatment – A Literature Review of Drug Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Safety, Efficacy, and Drug Survival of Biologics and Biosimilars for Moderate-To-Severe Plaque Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss32 - Cost-Effectiveness of Brodalumab for the Treatment of Moderate to Severe Plaque Psoriasis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy